Does the media favor PRTA or CGTX?

In the previous week, Cognition Therapeutics had 2 more articles in the media than Prothena. MarketBeat recorded 5 mentions for Cognition Therapeutics and 3 mentions for Prothena. Prothena's average media sentiment score of 1.31 beat Cognition Therapeutics' score of 0.00 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CGTX or CCCC?

In the previous week, Cognition Therapeutics had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Cognition Therapeutics and 2 mentions for C4 Therapeutics. Cognition Therapeutics' average media sentiment score of 0.00 beat C4 Therapeutics' score of -1.22 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media prefer KMDA or CGTX?

In the previous week, Cognition Therapeutics had 4 more articles in the media than Kamada. MarketBeat recorded 5 mentions for Cognition Therapeutics and 1 mentions for Kamada. Kamada's average media sentiment score of 0.00 equaled Cognition Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cognition Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CGTX or PRTC?

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 226.80%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, CGTX or PRTC?

Cognition Therapeutics has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.24 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is CGTX or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% PureTech Health N/A N/A N/A

Does the media prefer CGTX or PRTC?

In the previous week, Cognition Therapeutics had 4 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for Cognition Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Cognition Therapeutics' score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cognition Therapeutics (CGTX) Competitors

$1.02 -0.63 (-38.18%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 +0.06 (+6.37%)

As of 07:59 PM Eastern

Compare

CGTX vs. PRTA, CCCC, OVID, KMDA, and PRTC

Should you buy Cognition Therapeutics stock or one of its competitors? MarketBeat compares Cognition Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cognition Therapeutics include Prothena (PRTA), C4 Therapeutics (CCCC), Ovid Therapeutics (OVID), Kamada (KMDA), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry.

How does Cognition Therapeutics compare to Prothena?

Prothena (NASDAQ:PRTA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Prothena presently has a consensus target price of $23.75, indicating a potential upside of 152.66%. Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 226.80%. Given Cognition Therapeutics' higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Prothena has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

In the previous week, Cognition Therapeutics had 2 more articles in the media than Prothena. MarketBeat recorded 5 mentions for Cognition Therapeutics and 3 mentions for Prothena. Prothena's average media sentiment score of 1.31 beat Cognition Therapeutics' score of 0.00 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cognition Therapeutics has lower revenue, but higher earnings than Prothena. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	50.84	-$244.09M	-$2.82	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

97.1% of Prothena shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cognition Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Summary

Prothena beats Cognition Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cognition Therapeutics compare to C4 Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Cognition Therapeutics had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Cognition Therapeutics and 2 mentions for C4 Therapeutics. Cognition Therapeutics' average media sentiment score of 0.00 beat C4 Therapeutics' score of -1.22 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative

Cognition Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Cognition Therapeutics has higher earnings, but lower revenue than C4 Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
C4 Therapeutics	$35.95M	13.07	-$104.99M	-$1.19	N/A

Cognition Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market.

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 226.80%. C4 Therapeutics has a consensus price target of $7.75, indicating a potential upside of 82.35%. Given Cognition Therapeutics' higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

C4 Therapeutics beats Cognition Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Ovid Therapeutics has higher revenue and earnings than Cognition Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	64.36	-$17.41M	-$0.29	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Cognition Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Ovid Therapeutics currently has a consensus price target of $5.13, indicating a potential upside of 105.00%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 226.80%. Given Cognition Therapeutics' higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ovid Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

In the previous week, Cognition Therapeutics had 5 more articles in the media than Ovid Therapeutics. MarketBeat recorded 5 mentions for Cognition Therapeutics and 0 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.00 equaled Cognition Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Cognition Therapeutics	Neutral

Summary

Ovid Therapeutics beats Cognition Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Kamada?

Kamada (NASDAQ:KMDA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Kamada has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

Kamada has a net margin of 11.21% compared to Cognition Therapeutics' net margin of 0.00%. Kamada's return on equity of 7.73% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Kamada has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.28	$20.20M	$0.35	20.40
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

In the previous week, Cognition Therapeutics had 4 more articles in the media than Kamada. MarketBeat recorded 5 mentions for Cognition Therapeutics and 1 mentions for Kamada. Kamada's average media sentiment score of 0.00 equaled Cognition Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cognition Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada currently has a consensus price target of $12.00, suggesting a potential upside of 68.07%. Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 226.80%. Given Cognition Therapeutics' higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

20.4% of Kamada shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Kamada beats Cognition Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Cognition Therapeutics compare to PureTech Health?

Cognition Therapeutics (NASDAQ:CGTX) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Cognition Therapeutics has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Cognition Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 226.80%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PureTech Health's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
PureTech Health	N/A	N/A	N/A

In the previous week, Cognition Therapeutics had 4 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for Cognition Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Cognition Therapeutics' score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cognition Therapeutics beats PureTech Health on 8 of the 12 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGTX vs. The Competition

Export

Metric	Cognition Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$147.67M	$3.49B	$6.54B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-4.25	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	2.62	8.26	10.76	6.41
Net Income	-$23.49M	$23.91M	$3.56B	$337.14M
7 Day Performance	-28.17%	3.05%	1.37%	-0.48%
1 Month Performance	-19.05%	2.40%	0.81%	0.49%
1 Year Performance	240.00%	56.35%	30.53%	28.16%

Cognition Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGTX Cognition Therapeutics	3.8118 of 5 stars	$1.02 -38.2%	$3.33 +226.8%	+535.8%	$147.67M	N/A	N/A	20	News Coverage Analyst Forecast Gap Down High Trading Volume
PRTA Prothena	3.2995 of 5 stars	$8.25 -0.1%	$23.75 +187.9%	+57.6%	$431.91M	$9.68M	N/A	130	News Coverage Positive News Analyst Upgrade
CCCC C4 Therapeutics	1.4014 of 5 stars	$3.90 +0.8%	$7.75 +98.7%	+187.1%	$431.21M	$35.95M	N/A	150	News Coverage
OVID Ovid Therapeutics	2.1102 of 5 stars	$2.30 +4.1%	$5.13 +122.8%	+700.0%	$429.27M	$7.12M	N/A	60
KMDA Kamada	4.9158 of 5 stars	$7.44 flat	$12.00 +61.3%	-1.8%	$427.84M	$180.46M	21.26	360

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGTX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cognition Therapeutics (CGTX) Competitors

CGTX vs. PRTA, CCCC, OVID, KMDA, and PRTC

How does Cognition Therapeutics compare to Prothena?

Summary

How does Cognition Therapeutics compare to C4 Therapeutics?

Summary

How does Cognition Therapeutics compare to Ovid Therapeutics?

Summary

How does Cognition Therapeutics compare to Kamada?

Summary

How does Cognition Therapeutics compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cognition Therapeutics (CGTX) Competitors

CGTX vs. PRTA, CCCC, OVID, KMDA, and PRTC

How does Cognition Therapeutics compare to Prothena?

Do analysts rate PRTA or CGTX?

Which has more volatility and risk, PRTA or CGTX?

Does the media favor PRTA or CGTX?

Which has better valuation & earnings, PRTA or CGTX?

Do institutionals & insiders believe in PRTA or CGTX?

Is PRTA or CGTX more profitable?

Summary

How does Cognition Therapeutics compare to C4 Therapeutics?

Do insiders and institutionals believe in CGTX or CCCC?

Does the media refer more to CGTX or CCCC?

Is CGTX or CCCC more profitable?

Which has better earnings and valuation, CGTX or CCCC?

Which has more risk & volatility, CGTX or CCCC?

Do analysts prefer CGTX or CCCC?

Summary

How does Cognition Therapeutics compare to Ovid Therapeutics?

Which has higher earnings and valuation, OVID or CGTX?

Is OVID or CGTX more profitable?

Do analysts prefer OVID or CGTX?

Do insiders & institutionals believe in OVID or CGTX?

Which has more volatility and risk, OVID or CGTX?

Does the media prefer OVID or CGTX?

Summary

How does Cognition Therapeutics compare to Kamada?

Which has more risk & volatility, KMDA or CGTX?

Is KMDA or CGTX more profitable?

Which has stronger earnings and valuation, KMDA or CGTX?

Does the media prefer KMDA or CGTX?

Do analysts prefer KMDA or CGTX?

Do insiders & institutionals have more ownership in KMDA or CGTX?

Summary

How does Cognition Therapeutics compare to PureTech Health?

Which has stronger earnings & valuation, CGTX or PRTC?

Which has more risk & volatility, CGTX or PRTC?

Do analysts rate CGTX or PRTC?

Do insiders and institutionals have more ownership in CGTX or PRTC?

Is CGTX or PRTC more profitable?

Does the media prefer CGTX or PRTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools